Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy

Journal of Clinical Microbiology

Volumn 39, Issue 2, 2001, Pages 454-459

  Servais, J ^a   Lambert, C ^a   Fontaine, E ^a   Plesseria J M ^a   Robert, I ^a   Arendt, V ^a   Staub, T ^a   Schneider, F ^a   Hemmer, R ^a   Burtonboy, G ^a   Schmit, J C ^a  

^a Retrovirology Laboratory Luxembourg   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DNA SEQUENCE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRULENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INDINAVIR; MALE; MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0035122666     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.39.2.454-459.2001     Document Type: Article

References (26)

1. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
2. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 inhibitor
3. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
4. Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: Comparison with sequence analysis
5. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
6. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
7. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
8. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
9. Baseline HIV drug resistance profile predicts response to ritonavir/saquinavir protease inhibitor therapy in a community setting
10. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
11. Characterization of human immunodeficiency virus type 1 mutants with decreased susceptibility to proteinase inhibitor RO 31-8959
12. Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis
13. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
14. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor resistant variants in untreated subjects
15. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
16. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
17. Analysis HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
18. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
19. Mutations in retroviral genes associated with drug resistance
20. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
21. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations
22. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
23. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
24. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
25. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
26. HIV genotypic resistance patterns predicts response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed